Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...